Please describe your clinical practice in terms of Chronic and Frequent Episodic Migraine patients.

Do you have any history or relationship with the development of CGRPs as a class? If so which?

How concerned are you about the change from 12 weeks to 24 weeks for the first look at PROMISE 1 data?

Based on clinicaltrial.gov records it looks like enrollment has increased from 600 to 900 patients. How concerning is this to you? https://twitter.com/WilliamGerber1/status/852209231679893504/photo/1

How does the profile thus far of Eptinezumab look compared to Erenumab's STRIVE results?

What percent of the migraine population will use and IV vs. subcutaneous administration? Would that differ between frequent episodic vs. chronic migraine? What about IV administration would make it preferred vs. subcutaneous administration?  

How does the recently reported STRIVE and ARISE Ph3 data from Amgen shape your thoughts on which CGRP Ab therapy is best? How does eptinezumab stack up against the competition in both frequent episodic and chronic migraine? 

Do oral CGRP inhibitors currently in development have a realistic chance to succeed in the market based on what you know about safety and efficacy?

Any update on positive or negative safety/efficacy differences between receptor (Amgen) vs ligand (Alder, Teva, Lilly) CGRP inhibitors?

Any update on potential market size for CGRP inhibitors given Amgen/Novartis ARISE study only 1.1 day/month reduction vs placebo (2.9 vs 1.8 placebo) in episodic migraine and the STRIVE trial which showed 1.4 to 1.9 day reduction of episodic migraine day reduction vs placebo (3.2 to 3.7 vs 1.8 day). Are these reductions vs placebo going to create large demand?

What do you feel is the most important trial endpoint for CGRP inhibitors?  Average headache reduction days, percent 100% responders, 75% responders, 50% responders? Other?